In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until illness progression or even the participants are unable to tolerate the study drugs. Doable new approaches to the analysis and treatment of AML. (A) The identification https://abbv-744-cancer-treatment91245.fare-blog.com/32078836/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained